Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;69(4):103300.
doi: 10.1016/j.retram.2021.103300. Epub 2021 Jul 6.

Heparin beyond anti-coagulation

Affiliations
Review

Heparin beyond anti-coagulation

Daohong Chen. Curr Res Transl Med. 2021 Oct.

Abstract

Heparin has served as a mainstream anticoagulant for over eight decades. Clinically heparin-derived compounds significantly contribute to prevention and treatment of thrombotic events complicated in numerous medical conditions such as venous thromboembolism, coronary artery disease and extracorporeal circulation processes. Moreover in recent years, various off-labeled efficacious potentials of heparin beyond anti-coagulation are dramatically emerging, and increasingly investigated in clinical studies. Herein this article presents a comprehensive update on the expanded applications of heparin agents, covering the pregnant clinic, respiratory inflammation, renal disease, sepsis, pancreatitis, among others. It aims to maximize the beneficial profile of a pharmaceutical product through medical re-purposing development, exemplified by heparin, to address the unmet clinical needs of severe illness including coronavirus disease 2019 (COVID-19).

Keywords: Heparin; Medical re-purpose; Non-anticoagulant efficacy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Hemker H.C. A century for heparin: past, present and future. J Thromb Haemost. 2016;14:2329–2338. - PubMed
    1. Barrowcliffe T.W. History of heparin. Handb Exp Pharmacol. 2012;217:3–22. - PubMed
    1. Oduah E.I., Linhardt R.J., Sharfstein S.T. Heparin: past, present, and future. Pharmaceuticals. 2016;9:38. - PMC - PubMed
    1. Lima M., Rudd T., Yates E. New applications of heparin and other glycosaminoglycans. Molrcules. 2017;22:749. - PMC - PubMed
    1. Arepally G.M. Heparin-induced thrombocytopenia. Blood. 2017;129:2864–2872. - PMC - PubMed

MeSH terms